Therapeutic
proteins are engineered in the laboratory for pharmaceutical use,
including non-covalent binders. These proteins are highly effective
and serve as modernized treatment for rare as well as chronic
diseases. Protein therapeutics offer custom-made treatment approach
by supporting a specifically targeted therapeutic process by
compensating the deficiency of an essential protein. Recombinant
proteins have gained significant traction for therapeutic
applications and the number of proteins either launched or approved
into clinical trials has continually increased over the past two
decades. According to the National Center for Biotechnology
Information (NCBI) data of 2017, the U.S. Food and Drug
Administration (FDA) approved over 140 recombinant therapeutic
proteins for human use and several hundred are currently in
development. Majority of these proteins are recombinant monoclonal
antibodies.
Free
Request Sample of Report:
https://www.coherentmarketinsights.com/insight/request-sample/1981
The
global recombinant therapeutic antibodies and proteins market size
was valued at US$ 91.2 billion in 2017, and is expected to witness a
robust CAGR of 12.2% over the forecast period (2018 – 2026).
Integration
of novel approaches and strategies to modify protein drug products is
an important aspect. Advancements in recombinant protein technologies
have allowed drug manufacturers and developers to adjust required
functional characteristics of proteins of interest while maintaining
product efficacy and safety.
Various
recombinant technologies are currently in use to increase the
half-life, functionality, and targeting of novel therapeutic protein
drugs and increase product purity and volume. For instance, protein
conjugation and derivatization methods, including albumin-fusion15,
PEGylation and Fc-fusion are currently being used to extend a drug’s
circulating half-life.
Increasing
government support for novel drug development is expected to augment
the market growth
Governments
are supporting research and development of novel products due to
rapid advancements in biomedical science and technology to address
unmet medical needs. In 2012, the Food and Drug Administration Safety
and Innovation Act (FDASIA) was signed to provide the FDA with the
capability to establish breakthrough therapy designation (BTD), a new
program within the Expedited Programs for Serious Conditions. It was
designed to be available for drugs designed to treat a serious
condition and that have been shown to exhibit initial clinical
evidence of significant improvement over existing treatments.
Major
players operating in the global recombinant therapeutic antibodies
and proteins market include Abbott, Amgen Inc., Biogen Inc., Eli
Lilly and Company, F. Hoffmann-La Roche, Johnson and Johnson, Merck &
Co., Novo Nordisk, Pfizer Inc., and Sanofi S.A.
Detailed
Segmentation:
Global
Recombinant Therapeutic Antibodies and Proteins Market, By Drug
Class:
-
Plasma Protein
-
Growth Factors
-
Fusion Proteins
-
Monoclonal Antibodies
-
Hormones
-
Enzyme
-
Coagulation Factors
-
Others
Global
Recombinant Therapeutic Antibodies and Proteins Market, By
Application:
-
Oncology
-
Hematology
-
Immunology
-
Endocrinology
-
Infectious Disease
-
Cardiovascular Diseases
-
Others
Find
the comprehensive research report here with a single click:
https://www.coherentmarketinsights.com/market-insight/recombinant-therapeutic-antibodies-and-proteins-market-1981
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm
offering action-ready syndicated research reports, custom market
analysis, consulting services, and competitive analysis through
various recommendations related to emerging market trends,
technologies, and potential absolute dollar opportunity.
Contact
Us:
Mr.
Shah
Coherent
Market Insights
1001
4th Ave,
#3200
Seattle,
WA 98154
Tel:
+1-206-701-6702
No comments:
Post a Comment